American Home Products Corporation

Jacobus Pharmaceutical Company, Inc.

Other

Wyeth

Jacobus Pharmaceuticals Company, Inc.

Jacobus Pharmaceuticals, Inc.

Guy A Schiehser

Donald P Strike

Frances Christy Nelson

Magid A Abou-Gharbia

David Penman Jacobus

Wenyi Zhao

Hong-Ming Shieh

Craig E Caufield

Gavin David Heffernan

Nancie A Senko

Gregory F VonBurg

Amedeo A Failli

Jerauld S Skotnicki

Oleg I Bleyman

Norman P Jensen

Usha R Patel

Christina Louise Leone

Kurt E Steiner

Jacek Terpinski

Lisa A Marshall

Rajendra Shah

Gary Paul Stack

Arthur Attilio Santilli

John R Potoski

Kurt William Saionz

Timothy D Ocain

Daniel M Teller

Susan T Nielsen

Scott J Childress

Gregory F Von Burg

Charles Lin

Jerauld Stanley Skotnicki

David P Jacobus

The present invention relates to methods of determining the purity of a sample of 3,4-diaminopyridine comprising determining the presence, absence, or amount of a dimer of 3,4-diaminopyridine or a dimer of 3,4-diaminopyridine in the form of a salt, solvate or complex or a combination thereof. The invention also relates to methods of detecting and quantitating degradation in a sample of 3,4-diaminopyridine. Dimers of 3,4-diaminopyridine and methods of making and isolating the same are also provided.

Determining degradation of 3,4-diaminopyridine

The present invention relates to antimalarial compounds and their use against protozoa of the genus, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Heteroaryl derivatives and uses thereof

The present invention relates to antimalarial compounds and their use against protozoa of the genusincluding drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Aryl derivatives and uses thereof

Rapamycin hydroxyesters

Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

Biguanide and dihydrotriazine derivatives

A compound of the structure ##STR1## wherein X--Y is C.dbd.NOR.sup.1 or CHNHOR.sup.2 ; R.sup.1 and R.sup.2 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, alkyloxy, alkoxyalkyl, cycloalkylaminoalkyl, cyanoalkyl, fluoroalkyl, trifluoromethylalkyl, trifluoromethyl, ArO--, --(CH.sub.2).sub.m Ar, or --COR.sup.3 ;

Rapamycin 42-oximes and hydroxylamines

A compound of the structure ##STR1## wherein X-Y is C=NOR.sup.1 or CHNHOR.sup.2 ; R.sup.1 and R.sup.2 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, alkyloxy, alkoxyalkyl, cycloalkylaminoalkyl, cyanoalkyl, fluoroalkyl, trifluoromethylalkyl, trifluoromethyl, ArO--, --(CH.sub.2).sub.m Ar, or --COR.sup.3 ;

A compound of the structure ##STR1## wherein R and R.sup.1 are each, independently, ##STR2## or hydrogen; R.sup.2 and R.sup.3 are each, independently, alkyl, arylalkyl, or R.sup.2 and R.sup.3 may be taken together to form a cycloalkyl ring;

Hindered N-oxide esters of rapamycin

A compound of the structure ##STR1## wherein R and R.sup.1 are each independently, ##STR2## or hydrogen; R.sup.2 and R.sup.3 are each, independently, alkyl, arylalkyl, or R.sup.2 and R.sup.3 may be taken together to form a cycloalkyl ring;

A compound of the structure ##STR1## wherein R and R.sup.1 are each, independently, ##STR2## or hydrogen; R.sup.2 and R.sup.3 are each, independently, alkyl, arylalkyl , or R.sup.2 and R.sup.3 may be taken together to form a cycloalkyl ring;

A compound of the structure ##STR1## wherein R and R.sup.1 are each, independently, ##STR2## or hydrogen; R.sup.2 and R.sup.3 are each, independently, alkyl, arylalkyl , or R.sup.2 and R.sup.3 may be taken together to form a cycloalkyl ring; R.sup.4 is a heterocyclic N-oxide radical, which may be optionally substituted; R.sup.5 is alkyl or arylalkyl; R.sup.6 and R.sup.7 are taken together to form a saturated N-alkyl-heterocyclic N-oxide, which may be optionally substituted;

Growing community of inventors

Yardley, PA, United States of America

Guy A Schiehser